Compare Aterian Inc (ATER) vs Hims and Hers Health Inc (HIMS) Price & Performance

ATER trades at $0.47, down 2.56% today, with a bearish technical signal despite recent earnings beats. The company shows deteriorating fundamentals with revenue declining from $221M in 2022 to $69M in 2025 and negative net margins. However, positive developments include a pending asset sale expected to return $0.85-$1.14 per share to stockholders, with proxy advisors recommending approval.

The stock faces significant fundamental challenges with persistent losses and negative cash flow, but the proposed asset sale provides potential near-term catalyst. Analyst sentiment is divided with 50% buy ratings. Key risks include execution of the asset sale and ongoing operational losses, while the technical picture remains bearish near-term.

HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.

The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.